BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32600657)

  • 21. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer.
    Niederer-Wüst SM; Jochum W; Förbs D; Brändle M; Bilz S; Clerici T; Oettli R; Müller J; Haile SR; Ess S; Stoeckli SJ; Broglie MA
    Surgery; 2015 Jan; 157(1):119-25. PubMed ID: 25482468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
    Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
    Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The synergic effect of BRAF
    Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
    Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secondary histiocytic sarcoma with BRAF
    Venkataraman V; Massoth LR; Sullivan RJ; Friedmann AM
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29166. PubMed ID: 34061432
    [No Abstract]   [Full Text] [Related]  

  • 25. The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF
    Rossi ED; Bizzarro T; Granja S; Martini M; Capodimonti S; Luca E; Fadda G; Lombardi CP; Pontecorvi A; Larocca LM; Baltazar F; Schmitt F
    Endocrine; 2017 May; 56(2):379-387. PubMed ID: 27484771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic value of BRAF(V600E) mutation analysis of thyroid nodules according to ultrasonographic features and the time of aspiration.
    Moon HJ; Kim EK; Chung WY; Choi JR; Yoon JH; Kwak JY
    Ann Surg Oncol; 2011 Mar; 18(3):792-9. PubMed ID: 20945104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF mutation and RASSF1A expression in thyroid carcinoma of southern Italy.
    Santoro A; Pannone G; Carosi MA; Francesconi A; Pescarmona E; Russo GM; Feola A; Losito S; Franco R; Nappi L; Aquino G; De Rosa G; Di Domenico M; Bufo P
    J Cell Biochem; 2013 May; 114(5):1174-82. PubMed ID: 23192464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
    Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M
    Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of BRAF mutation and SUV
    Ozderya A; Temizkan S; Gul AE; Ozugur S; Sargin M; Aydin K
    Endocrine; 2017 Jan; 55(1):215-222. PubMed ID: 27696232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: A case report and review of the literature.
    Branco B; Comont T; Ysebaert L; Picard M; Laurent C; Oberic L
    Eur J Haematol; 2019 Oct; 103(4):444-448. PubMed ID: 31376203
    [No Abstract]   [Full Text] [Related]  

  • 31. BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas.
    Durante C; Tallini G; Puxeddu E; Sponziello M; Moretti S; Ligorio C; Cavaliere A; Rhoden KJ; Verrienti A; Maranghi M; Giacomelli L; Russo D; Filetti S
    Eur J Endocrinol; 2011 Sep; 165(3):455-63. PubMed ID: 21653734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allele-specific PCR with competitive probe blocking for sensitive and specific detection of BRAF V600E in thyroid fine-needle aspiration specimens.
    Smith GD; Zhou L; Rowe LR; Jarboe EA; Collins BT; Bentz JS; Wittwer CT; Chadwick BE
    Acta Cytol; 2011; 55(6):576-83. PubMed ID: 22156469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of BRAF V600E mutation in papillary thyroid carcinoma and tumor-surrounding nontumoral tissues.
    Dağlar-Aday A; Toptaş B; Oztürk T; Seyhan F; Saygili N; Eronat AP; Akadam-Teker B; Yilmaz-Aydoğan H; Aksoy F; Oztürk O
    DNA Cell Biol; 2013 Jan; 32(1):13-8. PubMed ID: 23157614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sonographic findings in three cases of carcinoma showing thymus-like differentiation.
    Yamamoto Y; Yamada K; Motoi N; Fujiwara Y; Toda K; Sugitani I; Kohno A
    J Clin Ultrasound; 2013; 41(9):574-8. PubMed ID: 23055246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
    Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
    Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
    Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.
    Kordes M; Röring M; Heining C; Braun S; Hutter B; Richter D; Geörg C; Scholl C; Gröschel S; Roth W; Rosenwald A; Geissinger E; von Kalle C; Jäger D; Brors B; Weichert W; Grüllich C; Glimm H; Brummer T; Fröhling S
    Leukemia; 2016 Apr; 30(4):937-46. PubMed ID: 26582644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis.
    Colanta A; Lin O; Tafe L; Ghossein R; Nafa K; Mitchell T; Ladanyi M; Arcila M
    Acta Cytol; 2011; 55(6):563-9. PubMed ID: 22156467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer.
    Abd Elmageed ZY; Sholl AB; Tsumagari K; Al-Qurayshi Z; Basolo F; Moroz K; Boulares AH; Friedlander P; Miccoli P; Kandil E
    Surgery; 2017 Apr; 161(4):1122-1128. PubMed ID: 27919446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.